Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741493 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT01741493: Completed Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01741493 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01741493, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and multiple dose study in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG Tofacitinib
- DRUG ABT-494
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT01741493 record still lists
NCT01741493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01741493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01741493 about?
NCT01741493 is a clinical study titled "A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494". This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and multiple dose study in healthy volunteers.
What is the current status of trial NCT01741493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2012-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01741493?
The interventions under investigation include: Placebo (DRUG), Tofacitinib (DRUG), ABT-494 (DRUG).
Who is sponsoring clinical trial NCT01741493?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01741493's enrollment target sits among peer trials
67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia